Glycated hemoglobin levels are mostly dependent on nonglycemic parameters in 9398 Finnish men without diabetes

The Journal of Clinical Endocrinology and Metabolism
Maria FizelovaMarkku Laakso

Abstract

Determinants of the variance in glycated hemoglobin (HbA1c) among individuals without type 2 diabetes remain largely unknown. We investigated the determinants of HbA1c, fasting plasma glucose, and 2-hour glucose in an oral glucose tolerance test and the associations of these glycemic markers with insulin sensitivity and insulin secretion in Finnish men without type 2 diabetes. The design and setting were the cross-sectional population-based Metabolic Syndrome in Men study including 10 197 Finnish men, aged 45-70 years, and randomly selected from the population register of Kuopio, Eastern Finland. Participants were a total of 9398 men without type 2 diabetes or with newly diagnosed type 2 diabetes at baseline (mean age 57 ± 7 y; body mass index 27.0 ± 4.0 kg/m(2), mean ± SD) in the Metabolic Syndrome in Men study cohort. The intervention included an oral glucose tolerance test. Glycemic and nonglycemic determinants of the variance in HbA1c among participants without type 2 diabetes and the association of HbA1c with insulin secretion and insulin sensitivity were measured. Age, fasting plasma glucose, and high-sensitivity C-reactive protein were the strongest determinants of HbA1c, explaining 12% of the variance in HbA1c levels in...Continue Reading

Citations

Jan 23, 2016·Acta Diabetologica·Ram JagannathanMichael Bergman
Apr 29, 2016·PloS One·Vicente Martínez-VizcaínoFernando Rodríguez-Artalejo
Jul 20, 2017·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A S MeijnikmanL F Van Gaal
Jul 13, 2021·Journal of Diabetes and Metabolic Disorders·Saeed Ebrahimi FanaFarideh Razi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.